12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TAK-875: Additional Phase II data

Additional data from a double-blind, international Phase II trial in 426 Type II diabetics who had not responded to metformin or diet and exercise alone showed that once-daily doses of 6.25, 25, 50, 100 and 200 mg TAK-875 significantly reduced mean HbA1c, the primary endpoint, by 0.65-1.12% from baseline to week 12 vs....

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >